Pages that link to "Q29619344"
Jump to navigation
Jump to search
The following pages link to Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (Q29619344):
Displaying 50 items.
- Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma (Q21129230) (← links)
- Targeting cancer-related inflammation: Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer (Q21132666) (← links)
- Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis (Q21133732) (← links)
- Erlotinib for advanced pancreatic cancer (Q24186983) (← links)
- Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer (Q24202423) (← links)
- Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer (Q24336620) (← links)
- Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients (Q24568136) (← links)
- Genetic and epigenetic alterations in pancreatic carcinogenesis (Q24598655) (← links)
- Recent progress in pancreatic cancer (Q24626346) (← links)
- Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma (Q24627664) (← links)
- Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer (Q24630174) (← links)
- Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer (Q24631880) (← links)
- Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283]. (Q24816432) (← links)
- How Grim is Pancreatic Cancer? (Q26740598) (← links)
- Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment (Q26740619) (← links)
- Pancreatic Cancer from Molecular Pathways to Treatment Opinion (Q26743482) (← links)
- Onivyde for the therapy of multiple solid tumors (Q26747166) (← links)
- Pancreatic cancer from bench to bedside: molecular pathways and treatment options (Q26747524) (← links)
- Systemic Chemotherapy in Advanced Pancreatic Cancer (Q26750440) (← links)
- Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan (Q26751368) (← links)
- Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers (Q26751473) (← links)
- Molecular therapeutics in pancreas cancer (Q26751709) (← links)
- Is metastatic pancreatic cancer an untargetable malignancy? (Q26753849) (← links)
- Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer (Q26764921) (← links)
- Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer (Q26765241) (← links)
- The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies (Q26765244) (← links)
- Genetics and biology of pancreatic ductal adenocarcinoma (Q26765438) (← links)
- Hedgehog Signaling in Pancreatic Fibrosis and Cancer (Q26766578) (← links)
- Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians (Q26767041) (← links)
- State of the art biological therapies in pancreatic cancer (Q26769941) (← links)
- Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly (Q26771399) (← links)
- Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies (Q26774636) (← links)
- Management of pancreatic cancer in the elderly (Q26774639) (← links)
- Viro-immune therapy: A new strategy for treatment of pancreatic cancer (Q26774641) (← links)
- Adjuvant therapy for pancreas cancer in an era of value based cancer care (Q26775916) (← links)
- Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update (Q26778004) (← links)
- Genomic alterations in pancreatic cancer and their relevance to therapy (Q26781443) (← links)
- Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials (Q26781538) (← links)
- More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds (Q26781662) (← links)
- The influence of subclonal resistance mutations on targeted cancer therapy (Q26781693) (← links)
- Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. (Q26786174) (← links)
- Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses (Q26786243) (← links)
- Novel agents for advanced pancreatic cancer (Q26787087) (← links)
- Perspectives in the treatment of pancreatic adenocarcinoma (Q26797248) (← links)
- Molecular Targeted Intervention for Pancreatic Cancer (Q26798453) (← links)
- Albumin-bound paclitaxel in solid tumors: clinical development and future directions (Q26798674) (← links)
- Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors (Q26799046) (← links)
- Novel adjuvant therapies for pancreatic adenocarcinoma (Q26799425) (← links)
- Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies (Q26799714) (← links)
- Current status and progress of pancreatic cancer in China (Q26799739) (← links)